Enanta (ENTA) CEO granted 310,000 stock options at $13.66

Enanta Pharmaceuticals Inc. (ENTA) reported a new equity award to its President and CEO, who also serves as a director.

Rhea-AI Filing Summary

Enanta Pharmaceuticals Inc. (ENTA) reported a new equity award to its President and CEO, who also serves as a director. On November 25, 2025, the insider received a stock option to purchase 310,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.

The option is scheduled to become exercisable in substantially equal quarterly installments over four years from the grant date, subject to the optionholder’s continued employment. Following this grant, the reporting person beneficially owns 310,000 derivative securities directly in the form of this stock option.

Insider Trade Summary

Grant/Award: 310,000 shares

Grant/Award 1 txn

Insider Luly Jay R.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	310,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 310,000 contracts (Direct)

Footnotes (1)

1. F1. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ENTA report in this Form 4?

ENTA reported that its President and CEO, who is also a director, was granted a stock option for 310,000 shares of Enanta common stock.

What is the exercise price of the new ENTA stock options?

The stock option has an exercise price of $13.66 per share for the underlying Enanta common stock.

When do the ENTA stock options granted on November 25, 2025 vest?

The option granted on November 25, 2025 becomes exercisable quarterly in substantially equal installments over four years, subject to continued employment.

How many ENTA derivative securities does the insider own after this transaction?

After the reported transaction, the insider beneficially owns 310,000 derivative securities, all in the form of this stock option.

What is the expiration date of the ENTA stock option granted to the CEO?

The stock option granted to the ENTA President and CEO expires on November 25, 2035.

Is the ENTA insider transaction a purchase of common stock or an option grant?

The reported transaction is a grant of a stock option to buy Enanta common stock, not a direct purchase of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luly Jay R.

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.66	11/25/2025		A		310,000		(1)	11/25/2035	Common Stock	310,000	$0.00	310,000	D

Explanation of Responses:

1. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

	/s/ Matthew Kowalsky as attorney-in-fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.